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Abstract
Purpose—In 2012, the American Urological Association released a revision of their 
asymptomatic microscopic hematuria (AMH) guidelines. Our objectives were to assess adherence 
to these guidelines and to describe the prevalence of urinary tract malignancy in postmenopausal 
women at our institution.
Materials and Methods—This is a cross-sectional analysis of women over age 55 evaluated by 
Urogynecology or Urology from 8/2012-8/2014 for a diagnosis of AMH. Women who underwent 
evaluation for ≥3 RBC/HPF on microscopic urinalysis were considered “true AMH.” Those who 
were evaluated after a dipstick with blood and had <3 RBC/HPF on urinalysis or no urinalysis 
were considered “positive dipstick.” Demographics, laboratory values, imaging results, and 
cystoscopy findings were extracted from electronic medical records.
Results—Our study population included 237 women (mean age 67.1±8.3 years). In our overall 
population 169/237(71.3%) had true AMH, 48/237(20.3%) had a positive dipstick, and 
20/237(8.4%) underwent evaluation in the setting of a urinary tract infection. We detected 3(1.4%) 
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urinary tract malignancies. One kidney cancer was identified in a 56 year-old, current smoker with 
a urine dipstick of 1+ blood. Two instances of bladder cancer were detected in women aged 58 and 
64, one current and one nonsmoker with 6 and 42 RBC/HPF on urinalyses respectively.
Conclusions—In postmenopausal women evaluated for AMH, the overall prevalence of urinary 
tract malignancy was low (1.4%). In our population, 28.7% underwent evaluation without meeting 
guideline criteria for AMH. This demonstrates an opportunity to improve adherence to existing 
guidelines to provide high-quality care and avoid unnecessary, expensive testing.
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Introduction
The prevalence of asymptomatic microhematuria (AMH) ranges from 2–30% depending on 
the definitions used and the age and gender of the population studied.1 AMH is clinically 
significant as it may be a sign of underlying urinary tract malignancy (including bladder and 
upper tract urothelial cancer), but there is often controversy regarding which patients should 
be investigated and if similar guidelines should be used for male and female patients.2,3 In 
2012, the American Urological Association (AUA) revised the AMH guidelines to maximize 
detection rates of urinary tract malignancies, but unfortunately the guidelines do not 
explicitly address gender-specific recommendations.1 In summary, the guidelines propose a 
thorough evaluation of any patient with three or greater red blood cells per high powered 
field (≥3RBC/HPF) on one properly collected urinary specimen in the absence of an obvious 
benign cause.1 They recommend cystoscopy for all patients over 35 years old as well as 
upper tract imaging using multi-phasic computed tomography (CT) urography. Since 
microhematuria may be intermittent, even when caused by malignancy, the guidelines 
specifically now require only one positive urine sample as opposed to the 2001 guidelines 
that required the presence of AMH in two out of three samples.4
The above recommendations may be appropriate in some patient populations, but 
postmenopausal women pose a unique challenge since bladder cancer is 3–4 times less 
common in females as compared to the equivalent male population5, while the prevalence of 
microhematuria is as high as 20.1% in postmenopausal women, presumably due to factors 
such as pelvic organ prolapse or vaginal atrophy.6 The AUA guidelines are vague as to how 
to consider these potentially confounding conditions in postmenopausal women and many 
clinicians pursue full AMH evaluations even if vaginal prolapse and atrophy are present, 
possibly leading to unnecessary, expensive testing and undue patient concern.
Furthermore, there are data that, in the primary care community, few patients with 
appropriately diagnosed AMH receive complete evaluations,7 but there are limited data on 
the urologic community’s adherence to AUA diagnostic criteria prior to initiation of AMH 
evaluation. The objective of this study was to describe adherence to AUA AMH guidelines 
by urology and urogynecology providers in a population of postmenopausal women at a 
tertiary care center. Additionally, we sought to assess the prevalence of urinary tract 
malignancy in our population of postmenopausal women.
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Materials and Methods
After Institutional Review Board approval, we performed a cross-sectional analysis of 
postmenopausal women evaluated for AMH at Duke University Medical Center. We used 
our electronic medical record to identify women who were evaluated by the Divisions of 
Urogynecology or Urology for ICD-9 codes 599.71 (gross hematuria), 599.7 (hematuria), 
599.70 (hematuria, unspecified) and 599.72 (microscopic hematuria) from 8/2012 to 8/2014. 
For purposes of our analysis, we only included women 55 years of age or older, and after 
medical records were reviewed, women with gross hematuria were excluded from our 
analysis. The AMH diagnosis was assigned by the clinician either based on a urine specimen 
sent from the initial office visit, or based on referral diagnosis for a new patient consultation.
Demographics, past medical and surgical histories, laboratory results, cystoscopy findings 
and imaging results were extracted from the medical record. For our study, the degree of 
hematuria was ascertained from the first positive urinalysis if multiple positive urinalyses 
were found. The American Urological Association (AUA) recommends further evaluation 
for AMH (defined as ≥3 RBC/HPF on microscopic urinalysis) when benign causes such as 
urinary tract infection (UTI) have been excluded. Women who underwent evaluation based 
on these guidelines were considered “true AMH”. Those who were evaluated after a dipstick 
with any blood and negative microscopic urinalysis (<3 RBC/HPF) or no microscopic 
urinalysis were considered “positive dipstick.” We also assessed for concomitant UTI, based 
on urine culture, at the time of urinalysis or dipstick analysis. A complete evaluation was 
defined per the AUA AMH guidelines as cystoscopy and upper tract imaging via multi-
phase computed tomography (CT) urography.
Data were analyzed using SPSS 22.0 (SPSS Inc., Chicago, IL). Results are presented as 
means with standard deviations (SD) for continuous normally distributed variables and 
medians with full ranges for continuous not normally distributed variables. Categorical 
variables are presented as counts and percentages.
Results
During our two year study period, we identified 348 hematuria diagnoses in women > 55 
years of age. After excluding those with gross hematuria, our study population included 237 
women with mean age 67.1±8.3 years. The majority of women were white (74.7%), 
nonsmokers (57.4%) and overweight (Body Mass Index [BMI] 28.1 ±5.9). Irritative voiding 
symptoms, defined as self-reported urinary urgency, frequency or nocturia, were reported in 
107/237 (45.1%) and 36/237 (15.2%) met one of the following definitions of recurrent 
urinary tract infection: 1) current antibiotic prophylaxis use; 2) ≥2 documented positive 
urine cultures in the last 6 months; or 3) ≥3 positive urine cultures in the last year.8 Oral or 
vaginal estrogen was used in 62/237 (27.0%) of patients.
Only 150/237 (63.3%) women underwent full genitourinary exam documenting vaginal 
tissue quality and presence of prolapse. Of these, 90/150 (60.0%) had objective atrophy. In 
this group, there was no prolapse in 134/150 (89.3%) and only 17/150 (11.3%) had stage II 
or greater prolapse on exam.
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Of the 228 women that had a microscopic urinalysis performed at some point in their 
evaluation, the mean number of RBC/HPF was 10.9 +/− 14.8 (range 0–117). In total, 40/228 
(17.5%) had <3 RBC/HPF, 123/228 (53.9%) had 3–10 RBC/HPF and 65/228 (28.5%) had 
>10 RBC/HPF. Of the microscopic urinalysis specimens, 206/237 (86.9%) were voided 
specimens, 19/237 (8.0%) were catheterized specimens and 12/237 (5.1%) had unknown 
collection methods.
With regards to our adherence to the AUA guidelines, in our overall population 169/237 
(71.3%) had true AMH, 48/237 (20.3%) had a positive dipstick, and 20/237 (8.4%) 
underwent evaluation for AMH in the setting of a urinary tract infection (UTI). Of these 20 
with UTI, only two women had follow up urinalyses documenting presence of AMH in the 
absence of infection. Additionally many patients were given a diagnosis of AMH without 
microscopic urinalysis. Only 60/237(25.3%) patients had a microscopic urinalysis sent on 
the same day that they had a dipstick that prompted referral or further evaluation for AMH. 
Amongst these 60 patients, there was a weak, positive correlation between urine dipstick 
amount and number of RBC/HPF (r=0.44 p<0.001). Of the remaining patients, 9/237 (3.8%) 
never had a microscopic urinalysis sent while 168/237 (70.9%) had urinalyses sent, but on a 
different date than their initial dipstick and often after they had already undergone expensive 
testing (cystoscopy and/or CT urogram).
In total, 210/237 (88.6%) women underwent complete evaluation, including 151/169 with 
true AMH and 59/68 with either positive dipstick or AMH in the setting of UTI. (Table 1) 
Amongst the patients with incomplete evaluation, 3 patients had magnetic resonance 
imaging (MRI) that was not specifically for urography and 1 patient had a renal ultrasound 
as their imaging modality. All women had a recently documented estimate of renal function.
Overall, among patients with complete evaluations, we detected 3/210 (1.4%) urinary tract 
malignancies. (Table 2) One woman with positive dipstick was diagnosed with kidney 
cancer. She was a 56 year-old, current smoker with a urine dipstick of 1+ blood without a 
full urinalysis. In those with true AMH, there were two instances of bladder cancer. They 
were in women aged 58 and 64, one current and one nonsmoker with 6 and 42 RBC/HPF on 
urinalysis respectively. Importantly, there were no patients with urinary tract malignancy that 
had only trace blood on initial dipstick analysis. In our study population we did not detect 
any intervention for nephrolithiasis. Of the 43/213 (20.2%) patients with benign renal cysts 
on imaging, none required intervention. Of patients that underwent cystoscopy, 12/234 
(5.1%) had a biopsy. Results included the two aforementioned bladder cancer cases and ten 
additional biopsies that resulted in findings of benign cystitis cystica.
Discussion
This study provides real-word insight into adherence to the current AUA asymptomatic 
microhematuria guidelines. In this cross-sectional study, we have several notable findings. 
Ultimately, 71.3% of patients were evaluated for a diagnosis of AMH that was adherent to 
the current AUA guidelines, but many of the urinalyses were sent after upper tract imaging 
and cystoscopy had already been performed. In our population of postmenopausal women, 
28.7% underwent evaluation for “hematuria” without actually being diagnosed with AMH or 
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had MH in the setting of a UTI. If referral or evaluation for AMH had been deferred until a 
confirmatory microscopic urinalysis had been sent or urine culture had resulted there would 
have been a significant decrease in the amount of expensive evaluations incurred by this 
patient population. As we are a tertiary care center, many of these patients were referred 
from primary care for a diagnosis of AMH and, in the majority of these cases, evaluation 
was likely initiated because of the patients’ presentation to a new provider for consultation. 
However, there were also evaluations initiated by either a urologic or urogynecologic 
provider after only a urinary dipstick showing MH. These variations in practice patterns may 
be amenable to interventions to improve workflows between primary care providers and 
specialists and is a potential target for quality improvement.
The greatest strength of our study is the size of the female, postmenopausal population 
reviewed and the number of patients with complete evaluations in order to comment on 
malignancy rates. Furthermore, since the data is based on real-world evaluation of patients, 
regardless of whether they met rigid AUA criteria for AMH; it is applicable to current 
practice patterns. The characteristics of our population of postmenopausal women are also 
consistent with other published studies. We had a high rate of recurrent UTI (15.2%) in our 
population that is inline with reported rates of bacteriuria and symptomatic UTI occurring in 
10%–15% of women aged 65–70 years and 15%–20% of women aged 80 years.9 This is an 
important factor in postmenopausal women that is not often discussed in risk factors for 
AMH. Since postmenopausal women have such a high rate of recurrent UTIs there could be 
low levels of persistent MH. This speculation is supported by the fact that the majority of the 
bladder biopsies performed in our study population were consistent with findings of cystitis 
cystica.
This study has several potential limitations that should be taken into consideration. Firstly, 
due to the retrospective, observational nature of our study, only 63.3% of patients had 
documented genitourinary exams. This limits our ability to comment on potentially 
confounding factors, such as atrophy or prolapse that may contribute to the presence of 
AMH. A significant proportion of patients with exams (60.0%) did have objective atrophy 
but we are unable to comment on the remainder of the patients. We know that estrogen 
deficiency after menopause causes atrophic changes within the urogenital tract. In addition 
to vaginal atrophy, these changes have been associated with urinary symptoms including 
frequency, urgency, nocturia, incontinence and recurrent infection.10,11 It is not unreasonable 
to assume that these atrophic changes to the bladder and urethra may lead to asymptomatic 
microhematuria in postmenopausal women although a direct link between urogenital 
atrophy and microhematuria has not been established. Although additional studies are 
needed in order to assess if it is safe to forego AMH evaluations in postmenopausal women 
with vaginal atrophy, clinicians should perform and document a genitourinary exam to 
determine if treatment of vaginal atrophy is necessary. Additionally, the higher presence of 
AMH (up to 20.1%)6,12,13 in women with pelvic organ prolapse, compared to the general 
population, despite a low risk of malignancy, has been used as an argument for separate 
AMH guidelines for women. Our particular population had a low rate of pelvic organ 
prolapse with only 11.3% of the documented exams with stage 2 or greater prolapse. This 
could limit generalizability of our data and the contribution of prolapse to AMH may be 
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significantly underestimated as upwards of 30% of postmenopausal women may have stage 
2 or greater prolapse on clinical exam.14
In our population of postmenopausal women evaluated for AMH, the overall prevalence of 
urinary tract malignancy was low, which is consistent with other published literature. 
Overall, regardless of gender, urinary tract malignancy rate amongst studies reviewed by the 
AUA was 3.3%1, but amongst studies evaluated by the AUA with large numbers of female 
patients, bladder cancer rates were noted to be 0–0.3%.15 As our data are consistent with the 
aforementioned studies, we again raise the question as to the most cost-effective screening 
strategies in this population. When considering large populations of patients, screening tests 
should not result in over-utilization of invasive testing, without improving the detection rate 
of malignancy - as this could actually result in harm. For example, the US Preventative 
Services Task Force (USPSTF) updated their breast cancer screening guidelines in 2009 to 
decrease mammographic frequency to limit unnecessary evaluations for benign breast 
disease.16 Improving gender-specific guidelines that allow for high detection rates of 
malignancies while limiting unnecessary evaluations is imperative for cost-effective health 
care. In the meantime, it is also of the utmost importance that providers adhere to the AUA 
guidelines and only pursue costly evaluations on patients who actually have AMH.
Importantly, in our study, we found all patients with urinary tract malignancy had 1+ or 
greater blood on initial dipstick analysis. We did not find any malignancy or clinically 
significant findings in patients with trace blood on dipstick. There was a weakly positive 
correlation between amount of blood on dipstick and level of hematuria. Studies have 
attempted to evaluate if urine dipsticks reliably predict microhematuria in various 
populations17, but additional research would need to be done in postmenopausal women to 
determine these associations. This would potentially lead to a decrease in the number of 
AMH evaluations for very low levels of microscopic hematuria and limit unnecessary 
testing.
Our data describes urinary tract malignancy rates in postmenopausal women evaluated for 
AMH and real-world adherence to the current AUA guidelines in the urology and 
urogynecologic community. In this cost-conscious era of health care it is important for 
clinicians to critically evaluate screening strategies. Our study not only demonstrates an 
opportunity to improve adherence to existing guidelines in consulting practices, but also that 
there is significant need for education in the primary care community. If microscopic 
urinalyses were universally sent as follow-up for dipstick tests concerning for AMH, a 
significant number of unnecessary referrals and evaluations might have been prevented.
Conclusion
This study provides important, real-world information on the adherence to the current AUA 
asymptomatic microhematuria guidelines in a tertiary care referral center. Our urinary tract 
cancer rate was low in our population of postmenopausal women, which continues to raise 
questions as to whether current guidelines are cost-effective for screening in this particular 
population.
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Future directions should include continued research into the confounding risk factors for 
AMH in postmenopausal women including vaginal atrophy, pelvic organ prolapse and 
recurrent urinary tract infection. Investigation into the exact correlation of urinary dipstick to 
microscopic urinalysis may also be a way to decrease the number of unnecessary and costly 
evaluations if definitive evidence shows that trace blood is not associated with AMH.
Key of Definitions for Abbreviations
AMH Asymptomatic Microscopic Hematuria
AUA American Urological Association
UTI Urinary Tract Infection
CT Computed Tomography
BMI Body Mass Index
RBC Red Blood Cells
HPF High Powered Field
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Table 1
AMH work-up and findings
Type of patient n (%)
Asymptomatic Microscopic Hematuria 169/237 (71.3%)
 Full work-up 151/169 (89.3%)
 No cystoscopy 3/169 (1.8%)
 No imaging* 15/169 (8.9%)
Positive Dipstick 48/237 (20.2%)
Positive dipstick, negative urinalysis 39/237 (16.5%)
Positive dipstick, no urinalysis sent 9/237 (3.8%)
Microscopic hematuria in setting of UTI 20/237 (8.4%)
 Full work-up 59/68 (86.8%)
 No imaging* 9/68 (13.2%)
*Also includes non-urography MRI or renal ultrasound
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Table 2
Imaging and Cystoscopy Findings
Finding n/N (%)
Urinary Tract Cancer 3/210 (1.4%)
 Bladder Cancer 2/210 (0.9%)
 Kidney Cancer 1/210 (0.5%)
Kidney Stone requiring Surgery 0/213 (0%)
Cystoscopy requiring Biopsy 12/234 (5.1%)
 Cystitis Cystica 10/12 (83.3%)
 Bladder cancer 2/12 (16.7%)
Imaging finding 70/213 (32.9%)
 Kidney mass 1/213 (0.5%)
 Non-obstructing stone 26/213 (12.2%)
 Benign Renal Cyst 43/213 (20.2%)
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